Pharmacogenetic Associations of beta 1-Adrenergic Receptor Polymorphisms with Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)
PublisherLippincott Williams and Wilkins
MetadataShow full item record
AbstractBackground and Purpose—Functional polymorphisms (Ser49Gly and Arg389Gly) in ADRB1 have been associated with cardiovascular and β-blocker response outcomes. Herein we examined associations of these polymorphisms with major adverse cardiovascular events (MACE), with and without stratification by β-blocker treatment in patients with a history of stroke. Methods—Nine hundred and twenty-six participants of the SPS3 trial’s (Secondary Prevention of Small Subcortical Strokes) genetic substudy with hypertension were included. MACE included stroke, myocardial infarction, and all-cause death. Kaplan–Meier and multivariable Cox regression analyses were used. Because the primary component of MACE was ischemic stroke, we tested the association of Ser49Gly with ischemic stroke among 41475 individuals of European and African ancestry in the NINDS (National Institute of Neurological Disorders and Stroke) SiGN (Stroke Genetics Network). Results—MACE was higher in carriers of the Gly49 allele than in those with the Ser49Ser genotype (10.5% versus 5.4%, log-rank P=0.005). Gly49 carrier status was associated with MACE (hazard ratio, 1.62; 95% confidence interval, 1.00–2.68) and ischemic stroke (hazard ratio, 1.81; 95% confidence interval, 1.01–3.23) in SPS3 and with small artery ischemic stroke (odds ratio, 1.14; 95% confidence interval, 1.03–1.26) in SiGN. In SPS3, β-blocker-treated Gly49 carriers had increased MACE versus non–β-blocker-treated individuals and noncarriers (hazard ratio, 2.03; 95% confidence interval, 1.20–3.45). No associations were observed with the Arg389Gly polymorphism. Conclusion—Among individuals with previous small artery ischemic stroke, the ADRB1 Gly49 polymorphism was associated with MACE, particularly small artery ischemic stroke, a risk that may be increased among β-blocker-treated individuals. Further research is needed to define β-blocker benefit among ischemic stroke patients by ADRB1 genotype. Copyright 2017 American Heart Association, Inc.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85016391633&doi=10.1161%2fSTROKEAHA.116.015936&partnerID=40&md5=3f59c3f32b91e026f803d9f14d9974bf; http://hdl.handle.net/10713/9926
- Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study.
- Authors: Andersson C, Mérie C, Jørgensen M, Gislason GH, Torp-Pedersen C, Overgaard C, Køber L, Jensen PF, Hlatky MA
- Issue date: 2014 Mar
- Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
- Authors: Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA
- Issue date: 2005 Sep 28
- beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke.
- Authors: Lemaitre RN, Heckbert SR, Sotoodehnia N, Bis JC, Smith NL, Marciante KD, Hindorff LA, Lange LA, Lumley TS, Rice KM, Wiggins KL, Psaty BM
- Issue date: 2008 Mar
- Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
- Authors: Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF Jr, Felker GM, Liggett SB, O'Connor CM, Bristow MR
- Issue date: 2018 Aug
- CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
- Authors: McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR
- Issue date: 2015 May 27